PRME · Prime Medicine
The AI's read
The report only lists after-market price moves and market caps. There is no company news about programs, trials, deals, or finances, so nothing here changes Prime Medicine's business view.
Prime Medicine shares rose 13.0% to $3.47 after-market; the piece only reports a price move and market cap, so the company's outlook is unchanged.
The report only lists after-market price moves and market caps. There is no company news about programs, trials, deals, or finances, so nothing here changes Prime Medicine's business view.
Onconetix shares rose 6.85% to $0.97 after-market; the article only reports the price change and market cap, so the company's outlook is unchanged.
Vogenx shares rose 6.52% to $25.78 after-market; the story only reports market moves and market cap, so it does not change the company's outlook.
PRF Technologies shares rose 5.89% to $1.04 after-market; the piece gives no business details beyond price and market cap, so outlook stays the same.
Jupiter Neurosciences shares rose 5.71% to $3.05 after-market; the article reports market moves only and does not change the company's outlook.
Senti Biosciences shares fell 17.1% to $0.28 after-market; the story only reports the price drop and market cap, so it does not change the company's outlook.
Follow Prime Medicine (PRME) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PRME